Anti-CBL (aa 736-835) polyclonal antibody

The objective of this work to evaluate the synergetic influence of UV and UV/H2O2 in the decomposition of carbaryl in the aqueous medium, various UV irradiation time in a range from (15-240 min) were investigated in the presence and absence of H2O2, for the removal of carbaryl (CBL) from an aqueous medium. The Gas-Chromatography coupled with mass spectrometry (GC-MS) and ion chromatography (IC) were applied to define the by-products and ionic species. The chemical properties such as total acidity, dissolved oxygen, and pH values were evaluated before and after irradiation in the presence and absence of H2O2. It was found that UV/H2O2 method has higher efficiency on the removal of carbaryl than UV irradiation alone. The complete mineralisation of CBL takes place at irradiation time 75 min using UV/H2O2. Decomposition pathway modelling for carbaryl was suggested based on the results obtained.

Epidermal growth factor receptor (EGFR) is highly expressed in head and neck squamous cell carcinoma (HNSCC) and related to cancer progression. The resistance to anti-EGFR therapy remains a major clinical problem in HNSCC. In this study, we found that TOLL-like receptor 4 (TLR4) was highly expressed in 50% of EGFR overexpressed HNSCC biopsies, which correlated to worse prognosis in patients. In HNSCC cell lines, activation of TLR4 reversed cetuximab-induced the inhibition of proliferation, migration and invasion. LPS induced of TLR4 signaling was potentiated under cetuximab treatment, showing increased activation of downstream NF-kappa B and MAPK pathways. Accordingly, cetuximab treatment also increased expression of TNF-alpha, COX2, and other molecules involved in TLR4 induced tumor inflammation. Mechanistically, we found inhibition of EGFR by cetuximab led to decreased phosphorylation of Src and sequentially Src-medicated activation of Cbl-b. This inhibited Cbl-b-mediated degradation of the key TLR4 adaptor protein MyD88 and activated TLR4 signaling. TLR4 or MyD88 overexpressed CAL27 and SCC4 cells grew faster and were more resistant to cetuximab and gefitinib both in vitro and in vivo. Out study delineates a crosstalk between EGFR and TLR4 pathways and identified TLR4 as a potential biomarker as well as a therapeutic target in overcoming the resistance to anti-EGFR therapy of HNSCC.